心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JAHA：NT‐proBNP在成年先心病患者中的预后价值

2018-04-04 MedSci MedSci原创

心血管先心病NT‐proBNP
关注

N末端B型利钠肽（NT‐proBNP）是成年先心病患者预后的可靠预测指标。本研究的目的旨在评估 NT‐proBNP在成年先心病患者中的水平以及其与心血管不良事件发生的相关性。本研究纳入了2011年至2013年门诊诊断的602名成年先心病患者，其中对595名（平均年龄为33岁，男性占58%，90%患者的纽约心功能分级为I级）患者的 NT‐proBNP水平进行了检测，并每年进行了随访，主要终点事件是死

N末端B型利钠肽（NT‐proBNP）是成年先心病患者预后的可靠预测指标。本研究的目的旨在评估 NT‐proBNP在成年先心病患者中的水平以及其与心血管不良事件发生的相关性。本研究纳入了2011年至2013年门诊诊断的602名成年先心病患者，其中对595名（平均年龄为33岁，男性占58%，90%患者的纽约心功能分级为I级）患者的 NT‐proBNP水平进行了检测，并每年进行了随访，主要终点事件是死亡、心衰、住院、心律失常血栓栓塞事件和心脏介入干预。经过平均4.4年时间的随访，共有199名患者出现主要终点事件，主要终点事件前一年的NT‐proBNP水平平均升高2.9 pmol/L，次要终点事件升高了18.2 pmol/L，而没有出现终点事件患者的仅升高了0.3 pmol/L（p＜0.001）。研究结果显示，成年先心病患者在出现心血管不良事件之前的NT‐proBNP水平是明显升高的，尤其是死亡和心衰。原始出处：Vivan J et al.Prognostic Value of Serial N‐Terminal Pro‐B‐Type Natriuretic Peptide Measurem

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1267783, encodeId=77ea126e7837b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289311, encodeId=628f128931174, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311472, encodeId=ecb313114e23c, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385208, encodeId=e9551385208b5, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601995, encodeId=7be0160199521, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=)]
    2018-04-06 zhaohui6731

    #AHA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1267783, encodeId=77ea126e7837b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289311, encodeId=628f128931174, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311472, encodeId=ecb313114e23c, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385208, encodeId=e9551385208b5, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601995, encodeId=7be0160199521, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=)]
    2018-04-06 huiwelcome

    #BNP#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1267783, encodeId=77ea126e7837b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289311, encodeId=628f128931174, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311472, encodeId=ecb313114e23c, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385208, encodeId=e9551385208b5, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601995, encodeId=7be0160199521, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=)]
    2018-04-06 ssnine

    #先心病#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1267783, encodeId=77ea126e7837b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289311, encodeId=628f128931174, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311472, encodeId=ecb313114e23c, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385208, encodeId=e9551385208b5, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601995, encodeId=7be0160199521, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=)]
    2018-04-06 paperyu

    #预后价值#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1267783, encodeId=77ea126e7837b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289311, encodeId=628f128931174, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311472, encodeId=ecb313114e23c, content=<a href='/topic/show?id=a12628e0852' target=_blank style='color:#2F92EE;'>#先心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28708, encryptionId=a12628e0852, topicName=先心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385208, encodeId=e9551385208b5, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601995, encodeId=7be0160199521, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Apr 06 00:21:00 CST 2018, time=2018-04-06, status=1, ipAttribution=)]
    2018-04-06 sunylz

    #PRO#

    0

相关资讯

Semin Arthritis Rheu：类风湿性关节炎、银屑病关节炎和银屑病预测心脏事件的心血管危险因素

女性RA患者和银屑病的额外心血管风险升高，而不是PsA。RA的全身炎症指标较高，而不是银屑病，表明这些病存在不同的心血管风险介质。

JACC：心衰与癌症的发生相关吗？

近期有研究表明，心衰患者发生癌症的风险要更高，然而这些研究的临床样本量较少，随访时间较短。本研究的目的旨在评估心衰是否与癌症及其相关死亡率相关。本研究纳入了2个1982年至1995年和1997年至2011年的内科医生健康调查随机临床对照研究，在初始分析时，研究者排除了一开始就有癌症或者心衰的患者，通过多变量调整Cox模型分析心衰与癌症发生的关系。在补充分析时，研究者纳入非癌症的70岁患者作为研究对

JACC：收缩压与急性主动脉夹层患者死亡率明显相关

收缩压（SBP）在许多心血管疾病中是一个预测患者死亡风险的有力工具。本研究的目的旨在评估SBP在预测急性主动脉夹层（AAD）患者的院内预后尤其是全因死亡率方面的作用。本研究纳入了数据库中6238名AAD患者（4167名患者为A型AAD，2071名为B型AAD），并根据患者的SBP分成4组：SBP >150， SBP 101 - 150， SBP 81 - 100和SBP ≤80 mm Hg。

JAHA：冠心病发病率竟与出生地有关？！

在国外出生的美国成年人的比例逐年增加，然而心血管疾病的发生是否与出生地点相关仍属未知。本研究的目的旨在评估比较不同地方出生的美国人的冠心病（CHD）和卒中发病率。本研究纳入了2006年至2014年国家健康调查的数据，将出生地分成美国和其他国家，其他国家又分成6大地区。分析结果发现，在美国的成年人中，16%是在其他国家出生的，与出生在其他国家的成年人相比，出生在美国的年龄标准化后的CHD发病率和卒中

NAT COMMUN：临床试验证明小分子可能改善心血管衰老

最近，来自科罗拉多大学博尔德分校的研究人员在一个2×6周的随机，双盲，安慰剂对照，交叉临床试验中找到了证据。

JAHA：慢阻肺患者SAVR和SAVR该如何选择？

慢性阻塞性肺疾病（COPD）患者在心脏手术后发生呼吸相关性并发症的风险更高。目前对于COPD患者，经导管主动脉瓣置换术（TAVR）和外科主动脉瓣置换术（SAVR）哪个预后更佳尚不清楚。本研究纳入了数据库中2011年至2014年年龄≥60岁，接受了TAVR或SAVR治疗的COPD患者，最终共纳入了相互匹配的1210名TAVR患者和1208名SAVR患者。分析结果显示，相比于接受SAVR患者，接受TA